BROCHURE

LC PHARMA FUND
 LUXBURG CAROLATH INVESTMENTS FUND SICAV | LC PHARMA FUND BROCHURE

LC PHARMA FUND ISIN: LI0562151964

• Absolute positive return objective

• Primary investment in medical cannabis

• 2 - 4 years investment horizon

The information in this BROCHURE is provided WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED.

5
INTRODUCTION

LC PHARMA FUND

Investing in Foundational Companies in the Emerging Global Cannabis

Industry.

LC Pharma Fund will make multiple investments in the cannabis industry

while navigating the rapidly changing cannabis industry dynamics.

LC MED AG as a fully licensed wholesaler for the distribution of medical

cannabis in Germany and the EU will be the first investment.

Our portfolio reflects the diversity in the legal medicinal cannabis supply
chain. From cultivation to development of new advanced medication like
individualized cannabis-based medicine for everyone, we are investing in
prime opportunities to enter a truly emerging industry.

With a market of over 742 million people and total healthcare spend of
€2.3t, Europe will be the largest medicinal cannabis market in the world.
It underlies an enormous growth potential with a projected worth of up to
€58b. After the Netherlands, Germany is the second largest medicinal
cannabis market in Europe.

7
LUXBURG CAROLATH INVESTMENTS FUND SICAV | LC PHARMA FUND BROCHURE LUXBURG CAROLATH INVESTMENTS FUND SICAV | LC PHARMA FUND BROCHURE

THE MEDICINAL CANNABIS THE MARKET OPPORTUNITY

VALUE CHAIN With a market of over 742 million people and total healthcare spend of €2.3t,
Europe will be the largest medicinal cannabis market in the world. It under-
The medicinal cannabis industry consists of four main parts: lies an enormous growth potential with a projected worth of up to €58b.
R&D, production and manufacturing, logistics and storage as well as After the Netherlands, Germany is the second largest medicinal cannabis
the sale of products. market in Europe.

EUROPE GERMANY
1. 2. 3. 4.
R&D Pharmaceutical Logistics / Sale of
manufacturing Storage products
R&D I
Advanced dosage
forms
Raw material
production
Warehouse Wholesale via
pharma wholesale
742 million 82.3 million
(cultivation) Logistics Population Population
Patient oriented Direct sale to
research Flower processing pharmacies
(extraction,
Medical research fractionation)

R&D II Advanced production

Medical research € 2.3t > 1 million
Total healthcare Cannabis patients
spend by 2024

MEDICINAL CANNABIS PRODUCTS € 58 billion € 7.7 billion

Estimated potential worth Estimated market volume
of the European medicinal medicinal cannabis by
cannabis market once all 2028
regulations are in place

€ 3.6 billion 200%

Flower Tinctures & oils Advanced dosage / Finished medicinal Estimated market volume Annual growth rate in the
Therapy forms products medicinal cannabis in German cannabis market
2021

8 9
LUXBURG CAROLATH INVESTMENTS FUND SICAV | LC PHARMA FUND BROCHURE LUXBURG CAROLATH INVESTMENTS FUND SICAV | LC PHARMA FUND BROCHURE

INVESTMENT LC PHARMA FUND

The LC Pharma Fund invests primarily into the pharmaceutical cannabis Overview of the sub-fund:
industry.
Security number 56.215.196
subscriptions: valuation
date, 12.00 midday
Among others into LC MED AG, a progressive pharmaceutical company ISIN number LI0562151964 redemptions: valuation
Closing date for
date, 12.00 midday,
in Germany, focused on the pharmaceutical cannabis market.Tested Sales are made to share transactions
with observance of a
professional investors
company value 2/2020 EUR 40 million. 2-4 times multiplier expected within Sales
and private investors in
12-month period of
notice
four years. Liechtenstein.

Duration of the
unlimited Redemptions are pos-
sub-fund sible at the earliest from
NAV 31/12/2022. The
Listing no lock-up period may be
Lock-up period extended a maximum of
Location Berlin Accounting currency two times by one year
EUR
of the sub-fund respectively in the event
of insufficient liquidity
Minimum investment EUR 100‘000.-- of the AIF.

Initial issue price EUR 1‘000.--

Denomination shares in three
Project LC MED AG, Advanced Pharmacy decimals
Initial subscription 09.09.2020
date
Payment under
subscription 15.09.2020 book entries / no
(first value date) Securitisation
certificates are issued
Evaluation AAA Valuation date last day of each year

Valuation interval annually Close of accounting each 31 December

year
at the latest on the last
Liechtenstein banking
Investment min. € 100,000 Valuation deadline day of the fifth month End of first
following the valuation 31 December 2021
business year
date

Day of issue and each valuation date Profit utilisation accumulative

redemption

Value date for each three banking days

Increase in value Multiplier 2-4x within four years day of issue and after valuation

10 11
LUXBURG CAROLATH INVESTMENTS FUND SICAV | LC PHARMA FUND BROCHURE LUXBURG CAROLATH INVESTMENTS FUND SICAV | LC PHARMA FUND BROCHURE

4. securities of any kind that are traded at a stock exchange or any other regulated market
INVESTMENT RULES OF THE
SUB-FUND 5. money market instruments;

6. demand deposits or time deposits with a duration of maximum twelve months with
The following terms regulate the sub-fund-specific investment rules of the
credit institutes with their registered office in a member state of the EEA or another state,
LC Pharma Fund.
if they are subject to regulation, that is equal to that of Liechtenstein;
A) Investment goal and investment policy
7. private placements (shares, obligations or notes that are placed without publicity by a
LC Pharma Fund invests primarily in one or more special purpose vehicles or unlisted
small number of banks or finance institutes; they are not listed on any exchange and are
investments (e.g. private equity, venture capital) with a focus on the pharmaceuticals
primarily acquired by institutional investors);
sector. The investments in such companies may occur on the one hand in the form of
equity securities. On the other hand, it is also possible to acquire debt securities issued
8. standardised derivative financial instruments of all kinds (in particular futures and
by the companies or to grant these securitised or unsecuritised loans.
options), the value of which is derived from investments (e.g. securities, precious metals,
raw materials), indices or reference rate (e.g. interest, currencies);
If no suitable investment opportunities are available on the market, the fund assets may
also be invested wholly in liquid funds for an extended time period. Similarly, investments
9. over-the-counter (OTC) options transactions
in traditional share classes are also possible, such as equity securities and investment
securities of all kinds, fixed or variable rate debt securities and claims (bonds, debentures,
10. over-the-counter (OTC) currency options and currency futures;
mortgage bonds, zero bonds etc.), convertible bonds and financial market instruments.

11. stock or shares in other alternative or traditional funds (incl. ETF);

The investments may be undertaken worldwide and in all freely-convertible currencies.
With regard to the quality of the securities and rights, there are essentially no limitations,
12. structured financial products of issuers worldwide;
i.e. assets may be acquired that are both of investment grade and non-investment grade.

B) Approved investments
The following are approved as investments of this sub-fund:
1. Equity securities and investment securities (shares, participation and participation
certificates, shares with warrants etc.) of unlisted companies (e.g. private equity, venture
capital) as well as special purpose vehicles (SPV) worldwide, with a focus on the pharma-
ceuticals sector;

2. fixed or variable rate debt securities and claims (shares, obligations, debentures, option
bonds, convertible bonds, mortgage bonds etc.) from private and public law debtors
worldwide;

3. issue of securitised/unsecuritised loans to special purpose vehicles (SPVs);

12 13
LUXBURG CAROLATH INVESTMENTS FUND SICAV | LC PHARMA FUND BROCHURE LUXBURG CAROLATH INVESTMENTS FUND SICAV | LC PHARMA FUND BROCHURE

STRUCTURE OF THE SUB-FUND LUXBURG CAROLATH INVESTMENTS

FUND SICAV
Registry No. FL-0002.602.993-8
Administration &
Investment Asset Management Settlement
Investors Committee Mag. Guenther Hotz Ahead Wealth
Board of Investors AHEAD Solutions AG
Liechtenstein

Umbrella
LUXBURG CAROLATH INVESTMENTS FUND SICAV

LC PHARMA FUND
ISIN: LI0562151964
Luxburg Carolath
Asset Management Luxburg Carolath Luxburg Carolath Value Invest
LC Pharma Fund
Fund Bank Fund Security House Fund Partner Fund
LI0562151964
LI0431275952 LI0431275978 LI0431275994 LI0595241428

Administrative Board
Ahead Wealth
Solutions AG
Custodian Bank Auditor Regulatory Authority
Liechtenstein Luxburg Carolath Investments Fund SICAV Alternative Investment Fund (AIF) established
SIGMA Bank AG Grant Thornton AG FMA
Liechtenstein Liechtenstein Liechtenstein in Liechtenstein (LI) pursuant to the Liechtenstein Law of 19. December 2012 regarding
Luxburg Carolath
Holding AG the Managers of Alternative Investment Funds (AIFMA) in the legal form of an investment
Switzerland
company with variable capital, structured as an umbrella fund comprising currently five
sub-funds and hereinafter referred to as “the Investment Company”.

The sub-funds are separate entities with regards to property law and liability, i.e. each
individual sub-fund is liable with its assets only for liabilities contracted by that particular
sub-fund. Additional sub-funds may be added at any time.

Luxburg Carolath Investments Fund SICAV is registered in Liechtenstein under the

number FL-0002.602.993-8 and regulated by the Financial Market Authority Liechtenstein
(FMA).

14 15
LUXBURG CAROLATH INVESTMENTS FUND SICAV | LC PHARMA FUND BROCHURE

DUE DILIGENCE

The necessary care in evaluating the investments and project developments

available is always guaranteed, among other things, by an external expert
opinion and the examination by the Investment Committee, which is
separate from the Supervisory Board, with additional recourse to proven
expert control. In doing so, great importance is attached to a maximum of
care and intensity. In particular, the economic viability of each individual
investment must withstand a third-party comparison.

16
LUXBURG CAROLATH INVESTMENTS FUND SICAV | LC PHARMA FUND BROCHURE LUXBURG CAROLATH INVESTMENTS FUND SICAV | LC PHARMA FUND BROCHURE

DISCLAIMER acc. to Liechtenstein law CONTACT DETAILS

This document is an advertisement. The Full details of the Fund can be found in the Key ORGANISATIONAL STRUCTURE OF THE “AIF” INVESTMENT COMPANY
information contained herein does not consti- Investor Information Document and the Pros- LUXBURG CAROLATH INVESTMENTS FUND SICAV AG
tute investment advice. Product information is pectus supplementing the most recent audited Country of incorporation Management of Ahead Wealth Solutions AG
not otherwise based on consideration of the annual report and the respective semi-annual Liechtenstein Alex Boss, Vaduz (LI)
personal circumstances of the recipient and is report, if more recent than the most recent Peter Bargetze, Triesen (LI)
not the result of an objective or independent annual report. These documents alone consti- Responsible regulatory authority Martin Krassnitzer, Bludesch (AT)
Finanzmarktaufsicht Liechtenstein (FMA)
financial analysis. The information provided tute the binding basis for an acquisition. As far
Landstrasse 109, 9490 Vaduz, Liechtenstein Asset Management
is not legally binding and does not constitute as tax or legal matters are concerned, these www.fma-li.li Mag. Guenther Hotz, Diepoldsau (CH)
an offer, invitation to tender or solicitation of should be discussed by the addressee with
financial transaction. his tax adviser or lawyer. The aforementioned Administrative board of the AIF Custodian Bank
sales documents are available free of charge Ahead Wealth Solutions AG, Vaduz (LI) SIGMA Bank AG
The document merely summarizes the main in electronic or printed form in German at the Luxburg Carolath Holding AG, Knonau (CH) Feldkircher Strasse 2, 9494 Schaan,
features of the Fund. The information has been fund administration, Ahead Wealth Solutions Liechtenstein
Administration/Management and Settlement
carefully compiled; partly using information AG, and the initiators of the fund.
of the AIF Auditor
from third parties. The information and opi- Ahead Wealth Solutions AG Grant Thornton AG
nions contained in this document represent the Units in funds may only be offered in countries Austrasse 15, 9490 Vaduz, Liechtenstein Bahnhofstrasse 15, 9494 Schaan,
views of the initiators at the time of prepara- where such offer or sale is permitted and / or Liechtenstein
tion. In particular, due to the passage of time, subject to local authority approval. In particu-
current developments in the markets and other lar, Shares of this Fund may not be offered for
material circumstances, information may prove sale or sold in the US or to or for the account of INVESTORS RELATIONS | BANK TO BANK SETTLEMENT
to be no longer or no longer fully applicable at US Citizens or US Persons resident in the US.
short notice. For the accuracy, completeness This information document and the informa- LCG Office Germany Admistration and Settlement Settlement Custodian Bank
Mr. E. Rupert Neukirchner Ahead Wealth Solutions AG For the subscription and Bank
and timeliness of all information is therefore tion it contains are not intended for use by US
Mob +49 151 1801 5902 Austrasse 15 to Bank settlement:
not guaranteed. No liability is accepted for any citizens or persons residing permanently in the Tel +49 30 34655 4000 9490 Vaduz, Liechtenstein [email protected]
damage or loss arising directly or indirectly United States, nor may they be distributed in Fax +49 30 34655 4040 Tel +423 2398 500
from the distribution or use of this product the United States. The distribution and publica- [email protected] Fax +423 2398 501 Contact persons are:
information or its contents. tion of this document may also be restricted in www.luxburgcarolath.fund [email protected] Ms. Isabel Wiedemann
other jurisdictions. www.ahead.li Mob +41 79 5609 995
Luxburg Carolath Group Tel +423 2390 476
When investing in mutual funds, there is a risk
Kurfuerstendamm 136 Asset Management Fax +423 2390 437
of price and currency losses, so that the future The information in this document is for additio- 10711 Berlin, Germany Mr. Guenther Hotz (Mag.)
value of the share may rise or fall compared nal information only and is protected by copy- [email protected] Mob +41 79 1574 569 Mr. Sven Wolfgruber
to the time of acquisition. If statements are right. No part of this information may be dis- www.luxburgcarolath.group [email protected] Tel +423 2390 478
made about market developments, yields, price tributed or reproduced in any form without the www.luxburgcarolath.fund
gains or other asset growth as well as risk written consent of the initiators of the Fund. SIGMA Bank AG
ratios, these only represent forecasts. These Feldkircher Strasse 2
9494 Schaan, Liechtenstein
assumptions need not occur. No assurances
[email protected]
are made about these forecasts. It should be www.sigmabank.com
noted that past performance, simulations or
projections are not a reliable indicator of future
performance.

18 19
WWW.LUXBURGCAROLATH.FUND